Abiopharma

🔍 Swayze Eric (Executive)

Company: IONIS PHARMACEUTICALS INC (IONS)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 5,125 shares of Common Stock at $60.89 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,578.00 | transaction_form_type: 4
• Sold 5,125 shares of Common Stock at $78.57 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,453.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 18,338 shares of Common Stock at $60.89 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 48,791.00 | transaction_form_type: 4
• Sold 18,338 shares of Common Stock at $79.27 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,453.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: by Son | shares_owned_after: 256.00
• Sold 5,125 shares of Non-Qualified Stock Option (right to buy) at $60.89 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2027-01-01 | Exercise: 2021-01-02 | equity_swap_involved: 0 | shares_owned_after: 22,403.00 | transaction_form_type: 4
• Sold 18,338 shares of Non-Qualified Stock Option (right to buy) at $60.89 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2027-01-01 | Exercise: 2020-01-02 | equity_swap_involved: 0 | shares_owned_after: 4,065.00 | transaction_form_type: 4
• Acquired 19,350 shares of Non-Qualified Stock Option (right to buy) at $79.67 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | Exercise: 2027-01-02 | equity_swap_involved: 0 | shares_owned_after: 19,350.00 | transaction_form_type: 4 | Footnotes: F4
• Acquired 150 shares of Non-Qualified Stock Option (right to buy) at $79.67 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | Exercise: 2027-01-02 | equity_swap_involved: 0 | shares_owned_after: 150.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
• F4: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.
• F5: Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.